Coherus BioSciences Inc
NASDAQ:CHRS
Balance Sheet
Balance Sheet Decomposition
Coherus BioSciences Inc
Coherus BioSciences Inc
Balance Sheet
Coherus BioSciences Inc
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
15
|
40
|
150
|
158
|
125
|
127
|
72
|
178
|
541
|
417
|
64
|
103
|
126
|
|
| Cash Equivalents |
15
|
40
|
150
|
158
|
125
|
127
|
72
|
178
|
541
|
417
|
64
|
103
|
126
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
128
|
15
|
0
|
|
| Total Receivables |
0
|
0
|
4
|
2
|
2
|
0
|
0
|
142
|
157
|
123
|
110
|
261
|
122
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
142
|
157
|
123
|
110
|
261
|
111
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
10
|
44
|
38
|
39
|
63
|
70
|
|
| Other Current Assets |
10
|
6
|
25
|
38
|
35
|
19
|
10
|
14
|
25
|
25
|
41
|
35
|
23
|
|
| Total Current Assets |
25
|
46
|
179
|
197
|
162
|
146
|
84
|
343
|
768
|
602
|
381
|
476
|
342
|
|
| PP&E Net |
2
|
2
|
5
|
11
|
11
|
13
|
7
|
17
|
20
|
16
|
14
|
11
|
7
|
|
| PP&E Gross |
2
|
2
|
5
|
11
|
11
|
13
|
7
|
17
|
20
|
16
|
14
|
11
|
7
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
4
|
6
|
10
|
13
|
16
|
16
|
17
|
20
|
21
|
21
|
|
| Intangible Assets |
0
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
6
|
71
|
54
|
|
| Goodwill |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
3
|
1
|
5
|
46
|
51
|
57
|
79
|
71
|
46
|
|
| Other Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
0
|
|
| Total Assets |
27
N/A
|
47
+79%
|
187
+295%
|
212
+13%
|
179
-16%
|
163
-9%
|
100
-39%
|
409
+311%
|
842
+106%
|
679
-19%
|
481
-29%
|
630
+31%
|
449
-29%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
2
|
3
|
9
|
26
|
20
|
16
|
15
|
26
|
15
|
16
|
12
|
35
|
28
|
|
| Accrued Liabilities |
4
|
7
|
11
|
24
|
25
|
9
|
18
|
89
|
129
|
148
|
126
|
293
|
229
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Liabilities |
6
|
39
|
32
|
56
|
12
|
4
|
0
|
0
|
1
|
0
|
0
|
3
|
25
|
|
| Total Current Liabilities |
11
|
54
|
52
|
106
|
56
|
28
|
33
|
115
|
146
|
165
|
139
|
332
|
283
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
100
|
102
|
103
|
178
|
405
|
409
|
473
|
474
|
293
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
6
|
36
|
69
|
113
|
3
|
2
|
2
|
10
|
10
|
8
|
7
|
16
|
4
|
|
| Total Liabilities |
17
N/A
|
90
+419%
|
120
+34%
|
219
+82%
|
158
-28%
|
131
-17%
|
138
+6%
|
304
+120%
|
561
+85%
|
582
+4%
|
618
+6%
|
823
+33%
|
581
-29%
|
|
| Equity | ||||||||||||||
| Common Stock |
55
|
55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
46
|
100
|
187
|
410
|
537
|
776
|
985
|
895
|
763
|
1 050
|
1 342
|
1 580
|
1 551
|
|
| Additional Paid In Capital |
1
|
3
|
254
|
404
|
559
|
808
|
947
|
1 001
|
1 044
|
1 148
|
1 204
|
1 386
|
1 419
|
|
| Other Equity |
0
|
0
|
1
|
0
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
9
N/A
|
42
N/A
|
67
N/A
|
6
N/A
|
21
N/A
|
32
+55%
|
39
N/A
|
105
N/A
|
281
+167%
|
98
-65%
|
137
N/A
|
193
-41%
|
132
+32%
|
|
| Total Liabilities & Equity |
27
N/A
|
47
+79%
|
187
+295%
|
212
+13%
|
179
-16%
|
163
-9%
|
100
-39%
|
409
+311%
|
842
+106%
|
679
-19%
|
481
-29%
|
630
+31%
|
449
-29%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
32
|
32
|
33
|
39
|
46
|
60
|
68
|
70
|
73
|
77
|
79
|
112
|
116
|
|